-
公开(公告)号:US20100322898A1
公开(公告)日:2010-12-23
申请号:US12771667
申请日:2010-04-30
CPC分类号: C07K14/54 , A61K38/193 , A61K38/20 , A61K38/2013 , A61K38/2026 , A61K38/2086 , A61K45/06 , C07K16/2878 , C07K2317/73 , Y02A50/463 , Y02A50/465 , Y02A50/475 , Y02A50/481
摘要: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
-
公开(公告)号:US20100316598A1
公开(公告)日:2010-12-16
申请号:US12763354
申请日:2010-04-20
CPC分类号: C07K14/54 , A61K38/193 , A61K38/20 , A61K38/2013 , A61K38/2026 , A61K38/2086 , A61K45/06 , C07K16/2878 , C07K2317/73 , Y02A50/463 , Y02A50/465 , Y02A50/475 , Y02A50/481
摘要: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
-
公开(公告)号:US20100316597A1
公开(公告)日:2010-12-16
申请号:US12763337
申请日:2010-04-20
CPC分类号: C07K14/54 , A61K38/193 , A61K38/20 , A61K38/2013 , A61K38/2026 , A61K38/2086 , A61K45/06 , C07K16/2878 , C07K2317/73 , Y02A50/463 , Y02A50/465 , Y02A50/475 , Y02A50/481
摘要: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
-
公开(公告)号:US20120294798A1
公开(公告)日:2012-11-22
申请号:US13535832
申请日:2012-06-28
IPC分类号: A61K38/20 , A61P35/02 , A61K51/08 , A61N5/00 , A61K38/21 , A61P37/04 , A61K39/00 , A61K39/395 , A61P35/00 , A61P37/02
CPC分类号: C07K14/54 , A61K38/193 , A61K38/20 , A61K38/2013 , A61K38/2026 , A61K38/2086 , A61K45/06 , C07K16/2878 , C07K2317/73 , Y02A50/463 , Y02A50/465 , Y02A50/475 , Y02A50/481
摘要: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
摘要翻译: 描述了使用具有IL-21功能活性的分子治疗具有癌症的哺乳动物的方法。 具有IL-21功能活性的分子包括与人IL-21多肽序列具有同源性的多肽和与具有IL-21功能活性的多肽融合的蛋白质。 分子可以用作单一疗法或与其他已知的癌症治疗剂组合使用。
-
公开(公告)号:US20100316600A1
公开(公告)日:2010-12-16
申请号:US12771142
申请日:2010-04-30
CPC分类号: C07K14/54 , A61K38/193 , A61K38/20 , A61K38/2013 , A61K38/2026 , A61K38/2086 , A61K45/06 , C07K16/2878 , C07K2317/73 , Y02A50/463 , Y02A50/465 , Y02A50/475 , Y02A50/481
摘要: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
摘要翻译: 描述了使用具有IL-21功能活性的分子治疗具有癌症的哺乳动物的方法。 具有IL-21功能活性的分子包括与人IL-21多肽序列具有同源性的多肽和与具有IL-21功能活性的多肽融合的蛋白质。 分子可以用作单一疗法或与其他已知的癌症治疗剂组合使用。
-
公开(公告)号:US20110002882A1
公开(公告)日:2011-01-06
申请号:US12762771
申请日:2010-04-19
CPC分类号: C07K14/54 , A61K38/193 , A61K38/20 , A61K38/2013 , A61K38/2026 , A61K38/2086 , A61K45/06 , C07K16/2878 , C07K2317/73 , Y02A50/463 , Y02A50/465 , Y02A50/475 , Y02A50/481
摘要: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
摘要翻译: 描述了使用具有IL-21功能活性的分子治疗具有癌症的哺乳动物的方法。 具有IL-21功能活性的分子包括与人IL-21多肽序列具有同源性的多肽和与具有IL-21功能活性的多肽融合的蛋白质。 分子可以用作单一疗法或与其他已知的癌症治疗剂组合使用。
-
公开(公告)号:US20100310505A1
公开(公告)日:2010-12-09
申请号:US12726989
申请日:2010-03-18
CPC分类号: C07K14/54 , A61K38/193 , A61K38/20 , A61K38/2013 , A61K38/2026 , A61K38/2086 , A61K45/06 , C07K16/2878 , C07K2317/73 , Y02A50/463 , Y02A50/465 , Y02A50/475 , Y02A50/481
摘要: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
-
公开(公告)号:US20100316599A1
公开(公告)日:2010-12-16
申请号:US12768970
申请日:2010-04-28
CPC分类号: C07K14/54 , A61K38/193 , A61K38/20 , A61K38/2013 , A61K38/2026 , A61K38/2086 , A61K45/06 , C07K16/2878 , C07K2317/73 , Y02A50/463 , Y02A50/465 , Y02A50/475 , Y02A50/481
摘要: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
-
公开(公告)号:US08383775B2
公开(公告)日:2013-02-26
申请号:US13339639
申请日:2011-12-29
申请人: Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
发明人: Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
CPC分类号: C07K14/001 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A61K38/00 , A61K38/18 , C07K14/52 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/715 , C07K16/24 , C07K16/2866 , C07K2317/73 , C07K2319/00 , C07K2319/21 , C07K2319/24 , C07K2319/30 , C07K2319/55 , C12N15/62 , C12N15/8509 , C12N2799/026 , G01N2333/52 , A61K2300/00
摘要: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
摘要翻译: 描述了与SEQ ID NO:2所示的包含zalpha11配体的序列的多肽和肽结合的抗体。 抗体可以结合162个氨基酸残基或其片段的全长序列,包括131个氨基酸残基的成熟多肽和较小的多肽和肽序列。 抗体可以包括多克隆,单克隆,鼠,人源化或中和的抗体。 还描述了产生抗体的方法。
-
公开(公告)号:US07998468B2
公开(公告)日:2011-08-16
申请号:US12469303
申请日:2009-05-20
申请人: Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
发明人: Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
CPC分类号: C07K14/001 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A61K38/00 , A61K38/18 , C07K14/52 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/715 , C07K16/24 , C07K16/2866 , C07K2317/73 , C07K2319/00 , C07K2319/21 , C07K2319/24 , C07K2319/30 , C07K2319/55 , C12N15/62 , C12N15/8509 , C12N2799/026 , G01N2333/52 , A61K2300/00
摘要: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
摘要翻译: 描述了与SEQ ID NO:2所示的包含zalpha11配体的序列的多肽和肽结合的抗体。 抗体可以结合162个氨基酸残基或其片段的全长序列,包括131个氨基酸残基的成熟多肽和较小的多肽和肽序列。 抗体可以包括多克隆,单克隆,鼠,人源化或中和的抗体。 还描述了产生抗体的方法。
-
-
-
-
-
-
-
-
-